ALLEGAN, Mich., Feb. 1 /PRNewswire-FirstCall/ -- The Perrigo Company
(Nasdaq: PRGO; TASE) today announced that the Board of Directors has
authorized the repurchase of $150 million of the Company's common stock
through February 1, 2010 under its ongoing share repurchase program. Any
remaining balance of the previously authorized program will expire on
February 8, 2009. Under share repurchase programs since November 2000,
Perrigo has repurchased 11.4 million shares at a cost of approximately $174
million. As of January 25, 2008, Perrigo had 93,080,386 common shares
outstanding.
The Company also announced that its Board of Directors declared a
quarterly dividend of $0.05 per share, payable on March 18, 2008 to
shareholders of record on February 22, 2008.
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes over-the-counter (OTC) and prescription
pharmaceuticals, nutritional products, active pharmaceutical ingredients
(API) and consumer products. The Company is the world's largest
manufacturer of OTC pharmaceutical products for the store brand market. The
Company's primary markets and locations of manufacturing facilities are the
United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the
Internet (http://www.perrigo.com).
SOURCE The Perrigo Company
 back to top
Related links:
http://www.perrigo.com/
CONTACT:
Arthur J. Shannon, Vice President, Investor
Relations and Communication, +1-269-686-1709,
ajshannon@perrigo.com, or Ernest J. Schenk, Manager, Investor
Relations and Communication, +1-269-673-9212,
eschenk@perrigo.com, both of The Perrigo Company
|
